

## Special Issue

# Tuberculosis Diagnostic, Treatments and Vaccines Research

### Message from the Guest Editor

BCG (Bacillus Calmette–Guérin) remains the only effective vaccine against tuberculosis. Its discovery early in the 20th century allowed a drastic reduction in children mortalities. However, the vaccine has been shown to provide variable protection in adults against pulmonary tuberculosis. Novel and more effective strategies, including new vaccines or different use of BCG, are now essential to reduce the prevalence of the disease and foresee its eradication. TB diagnosis is particularly difficult in immuno-compromised individuals or children. In this regard, the latest WHO report highlights improvements in TB diagnostics and shortening the time to initiate appropriate treatment as key priorities. For this Special Issue of *Vaccines*, we kindly invite authors to submit an original research article or a review focusing on the recent advances to diagnose, prevent or treat TB. Potential topics could include (but are not limited to): new treatment strategies, vaccine studies, or the setting up of a new diagnostic test.

---

### Guest Editor

Dr. Machelart Arnaud

Institut Pasteur de Lille, Centre d'Infection et d'Immunité de Lille, Université de Lille, CNRS UMR9017, INSERM U1019, CHU Lille, 59000 Lille, France

---

### Deadline for manuscript submissions

closed (30 November 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/108453](https://mdpi.com/si/108453)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).